Shares of Terns Pharmaceuticals hovered near the acquisition offer price from Merck & Co. in premarket trading Thursday, following the announcement of a definitive agreement for Merck to purchase the biotechnology firm. The stock was indicated at $52.86, a mere $0.14 discount to the $53 per share all-cash tender offer, reflecting market confidence in the transaction's closure. This follows a significant 5.8% surge in Terns' share price during Wednesday's regular session.
Strategic Acquisition for Merck's Pipeline
The deal, valued at approximately $6.7 billion in equity value, or roughly $5.7 billion net of cash, represents a strategic move by Merck to bolster its hematology portfolio. The acquisition is centrally focused on Terns' lead asset, TERN-701, an oral tyrosine kinase inhibitor (TKI) designed to treat chronic myeloid leukemia (CML). In the Phase 1/2 CARDINAL trial, the drug demonstrated a 75% major molecular response rate at 24 weeks among evaluable patients receiving the recommended dose, a metric indicating a substantial reduction in leukemia-driving cells.
Merck CEO Robert Davis framed the acquisition as an initiative that "builds on our growing presence in hematology." The move is also seen as part of a broader strategy to diversify Merck's revenue base ahead of the 2028 loss of U.S. market exclusivity for its blockbuster cancer therapy Keytruda. Terns CEO Amy Burroughs highlighted Merck's "scale and resources" as critical for advancing TERN-701 through later-stage development and potential commercialization.
Market Reaction and Analyst Commentary
Trading volume exploded to 81.3 million shares on Wednesday, a stark increase from the 2.5 million shares traded the prior session, after news of the pending deal broke. The narrow spread between the trading price and the offer price suggests investors largely expect the deal to proceed as outlined.
Analysts were quick to provide context. The acquisition draws immediate comparison to Novartis's Scemblix, a established therapy in the CML space. William Blair analyst Andy Hsieh suggested Merck may not be paying for the drug's full long-term potential. Conversely, RBC Capital Markets analyst Trung Huynh projected that multibillion-dollar peak sales for TERN-701 are "realistic," contingent upon the drug confirming its efficacy and durability in subsequent trials. Some investors expressed hope for a higher price, especially with additional clinical data for TERN-701 expected later in 2026.
Deal Mechanics and Potential Hurdles
The transaction is structured as a tender offer followed by a merger, anticipated to close in the second quarter of 2026. It is not yet finalized, however. Completion requires more than 50% of Terns' outstanding shares to be tendered and is subject to customary antitrust approvals.
The merger agreement includes a no-shop provision preventing Terns from actively soliciting alternative offers, though it does allow the board to consider unsolicited superior proposals. A termination fee structure is in place: Terns would owe Merck $235 million if it accepts a superior bid, while Merck would owe Terns $270 million if the deal fails due to antitrust objections.
Possibility of a Competing Bid
The relatively modest 6% acquisition premium has led some observers, including RBC's Huynh, to speculate that other pharmaceutical companies like AbbVie or Bristol Myers Squibb could potentially emerge with competing offers. The current stock price, holding just below the $53 mark, indicates the market is closely monitoring both the likelihood of the existing deal closing and the potential for a bidding contest to emerge.
Ultimately, the acquisition underscores the premium large pharmaceutical companies are willing to pay for promising mid-stage assets that can address significant unmet medical needs and diversify revenue streams. For Terns shareholders, the offer provides a near-term liquidity event at a substantial premium to recent trading levels, while for Merck, it represents a calculated bet on the future of its oncology franchise beyond Keytruda.
